Fatal Acute tumor lysis syndrome following intrathecal chemotherapy for acute lymphoblastic leukemia with meningeal involvement

Internal Medicine

Volumn 47, Issue 22, 2008, Pages 1987-1988

  Konuma, Takaaki ^a   Ooi, Jun ^a   Takahashi, Satoshi ^a   Tomonari, Akira ^a   Tsukasa, Nobuhiro ^a   Kato, Seiko ^a   Sato, Aki ^a   Monma, Fumihiko ^a   Uchimaru, Kaoru ^a   Tojo, Arinobu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Acute lymphoblastic leukemia; Intrathecal chemotherapy; Tumor lysis syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOBUTAMINE; DOPAMINE; HYDROCORTISONE; LOOP DIURETIC AGENT; METHOTREXATE; PHOSPHORUS; POTASSIUM;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW BIOPSY; CANCER RELAPSE; CASE REPORT; CONGESTIVE HEART FAILURE; CONVULSION; CORD BLOOD STEM CELL TRANSPLANTATION; DEATH; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; LOW DRUG DOSE; LUMBAR PUNCTURE; MENINGEAL METASTASIS; MULTIPLE CYCLE TREATMENT; OLIGURIA; PATIENT MONITORING; PLEOCYTOSIS; RETINA DETACHMENT; SHORT TANDEM REPEAT; TUMOR LYSIS SYNDROME; VISUAL IMPAIRMENT; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FATAL OUTCOME; FEMALE; HUMANS; INJECTIONS, SPINAL; LEUKEMIC INFILTRATION; MENINGEAL NEOPLASMS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR LYSIS SYNDROME;

EID: 59849088775     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1456     Document Type: Article

References (6)

1. Cario MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3-11, 2004.
2. Benekli M, Güllü IH, Savas MC, et al. Acute tumor lysis syndrome following intrathecal methotrexate. Leuk Lymphoma 22: 361-363, 1996.
3. Simmons ED, Somberg KA. Acute tumor lysis syndrome after intrathecal methotrexate administration. Cancer 67: 2062-2065, 1991.
4. Barista I, Celik I, Güllü IH, Yalçin S. Intrathecal chemotherapy and bone marrow. Leukemia II: 1392-1393, 1997.
5. Barista I. Intrathecal cytarabine and bone marrow suppression. J Clin Oncol 18: 2003-2004, 2000.
6. Jacobs SA, Bleyer WA, Chabner BA, Johns DG. Letter: Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1: 465-466, 1975.